Toggle Main Menu Toggle Search

Open Access padlockePrints

Efficacy and Safety of Strontium Ranelate in the Treatment of Osteoporosis in Men

Lookup NU author(s): Emeritus Professor Roger Francis


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Context: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal osteoporosis. Objective: The objective of this study was to determine the efficacy and safety of strontium ranelate in osteoporosis in men over 2 years (main analysis after 1 year). Design: This was an international, unbalanced (2: 1), double-blind, randomized placebo-controlled trial (MALEO [MALE Osteoporosis]). Setting: This international study included 54 centers in 14 countries. Participants: Participants were 261 white men with primary osteoporosis. Intervention: Strontium ranelate at 2 g/d (n = 174) or placebo (n = 87) was administered. Main Outcome Measures: Lumbar spine (L2-L4), femoral neck, and total hip bone mineral density (BMD), biochemical bone markers, and safety were measured. Results: Baseline characteristics were similar in both groups in the whole population (age, 72.9 +/- 6.0 years; lumbar spine BMD T-score, -2.7 +/- 1.0; femoral neck BMD T-score, -2.3 +/- 0.7). Men who received strontium ranelate over 2 years had greater increases in lumbar spine BMD than those who received placebo (relative change from baseline to end, 9.7% +/- 7.5% vs 2.0% +/- 5.5%; between-group difference estimate (SE), 7.7% (0.9%); 95% confidence interval, 5.9%-9.5%; P < .001). There were also significant between-group differences in relative changes in femoral neck BMD(P < .001) and total hip BMD (P < .001). At the end of treatment, mean levels of serum cross-linked telopeptides of type I collagen, a marker of bone resorption, were increased in both the strontium ranelate group (10.7% +/- 58.0%; P = .022) and the placebo group (34.9% +/- 65.8%; P < .001). The corresponding mean changes of bone alkaline phosphatase, a marker of bone formation, were 6.4% +/- 28.5% (P = .005) and 1.9% +/- 25.4% (P = .505), respectively. After 2 years, the blood strontium level (129 +/- 66 mu mol/L) was similar to that in trials of postmenopausal osteoporosis. Strontium ranelate was generally well tolerated. Conclusions: The effects of strontium ranelate on BMD in osteoporotic men were similar to those in postmenopausal osteoporotic women, supporting its use in the treatment of osteoporosis in men. (J Clin Endocrinol Metab 98: 592-601, 2013)

Publication metadata

Author(s): Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Endocrinology and Metabolism

Year: 2013

Volume: 98

Issue: 2

Pages: 592-601

Print publication date: 01/02/2013

ISSN (print): 0021-972X

ISSN (electronic): 1945-7197

Publisher: The Endocrine Society


DOI: 10.1210/jc.2012-3048


Altmetrics provided by Altmetric